Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes

Arthritis Rheum. 2002 Jan;46(1):42-51. doi: 10.1002/1529-0131(200201)46:1<42::AID-ART10026>3.0.CO;2-A.

Abstract

Objective: To determine the direct effect of cyclosporin A (CSA) on the production of cytokines by rheumatoid synovial fibroblasts.

Methods: Fibroblast-like synoviocytes (FLS) were prepared from the synovial tissues of patients with rheumatoid arthritis and cultured in the presence of CSA. The production of interleukin-10 (IL-10), IL-15, and tumor necrosis factor a (TNFalpha) by FLS was measured in culture supernatants by enzyme-linked immunosorbent assay. The expression of IL-10, IL-15, and TNFalpha messenger RNA (mRNA) in FLS was determined by polymerase chain reaction (PCR).

Results: CSA (1-1,000 ng/ml) increased the production of IL-10, but decreased in a dose-dependent manner the levels of IL-15 and TNFalpha that were spontaneously secreted from FLS. CSA also potently inhibited the production of IL-15 and TNFalpha stimulated with interferon-gamma, IL-1beta, or lipopolysaccharide. The inhibitory effect of CSA on IL-15 and TNFalpha production depended on the increase in IL-10, since neutralizing anti-IL-10 antibodies were able to partially reverse this inhibition. In a semiquantitative PCR, CSA increased IL-10 mRNA expression but strongly suppressed IL-1beta-induced IL-15 and TNFalpha mRNA expression, indicating that the production of these cytokines by CSA was regulated at the transcriptional level. Results with the calcineurin inhibitor FK-506, but not with the immunosuppressant rapamycin, were similar to those with CSA. Agonists of cAMP displayed an additive effect on the changes produced in the IL-10, IL-15, and TNFalpha levels by CSA, while a cAMP antagonist almost completely abrogated the effect of CSA, suggesting that cAMP is the major intracellular signal that mediates cytokine regulation by CSA.

Conclusion: These results suggest that CSA differentially regulates the production of cytokines by rheumatoid synoviocytes via a cAMP-dependent pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-3-isobutylxanthine / pharmacology
  • Antimetabolites / pharmacology
  • Antirheumatic Agents / pharmacology*
  • Arthritis, Rheumatoid / immunology*
  • Bucladesine / pharmacology
  • Calcineurin Inhibitors
  • Cells, Cultured
  • Cyclic AMP / metabolism
  • Cyclosporine / pharmacology*
  • Cytokines / genetics*
  • Cytokines / immunology
  • Dideoxyadenosine / pharmacology
  • Fibroblasts / cytology
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism
  • Gene Expression / drug effects
  • Gene Expression / immunology
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Interleukin-10 / genetics
  • Interleukin-10 / immunology
  • Interleukin-15 / genetics
  • Interleukin-15 / immunology
  • Phosphodiesterase Inhibitors / pharmacology
  • RNA, Messenger / analysis
  • Synovial Membrane / cytology*
  • Tacrolimus / pharmacology
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Antimetabolites
  • Antirheumatic Agents
  • Calcineurin Inhibitors
  • Cytokines
  • Immunosuppressive Agents
  • Interleukin-15
  • Phosphodiesterase Inhibitors
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Dideoxyadenosine
  • Bucladesine
  • Cyclosporine
  • Cyclic AMP
  • 1-Methyl-3-isobutylxanthine
  • Tacrolimus